137 related articles for article (PubMed ID: 17886625)
1. Serum level of intact parathyroid hormone and other markers of bone metabolism in dialyzed patients.
Grzegorzewska AE; Młot-Michalska M
Adv Perit Dial; 2007; 23():162-5. PubMed ID: 17886625
[TBL] [Abstract][Full Text] [Related]
2. Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease.
Grzegorzewska AE; Młot M
Rocz Akad Med Bialymst; 2004; 49():190-2. PubMed ID: 15631341
[TBL] [Abstract][Full Text] [Related]
3. Serum markers of bone turnover in dialyzed patients grouped by level of intact parathyroid hormone.
Grzegorzewska AE; Mlot-Michalska M
Adv Perit Dial; 2006; 22():203-6. PubMed ID: 16983970
[TBL] [Abstract][Full Text] [Related]
4. Serum markers of bone turnover in dialyzed patients separated according to age.
Grzegorzewska AE; Młot M
Int Urol Nephrol; 2006; 38(2):311-6. PubMed ID: 16868703
[TBL] [Abstract][Full Text] [Related]
5. Association between phosphate removal and markers of bone turnover in haemodialysis patients.
Albalate M; de la Piedra C; Fernández C; Lefort M; Santana H; Hernando P; Hernández J; Caramelo C
Nephrol Dial Transplant; 2006 Jun; 21(6):1626-32. PubMed ID: 16490746
[TBL] [Abstract][Full Text] [Related]
6. Impact of lowering dialysate calcium concentration on serum bone turnover markers in hemodialysis patients.
Hamano T; Oseto S; Fujii N; Ito T; Katayama M; Horio M; Imai E; Hori M
Bone; 2005 May; 36(5):909-16. PubMed ID: 15794928
[TBL] [Abstract][Full Text] [Related]
7. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
[TBL] [Abstract][Full Text] [Related]
8. Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones.
Grzegorzewska AE; Młot M
Rocz Akad Med Bialymst; 2004; 49():193-6. PubMed ID: 15631342
[TBL] [Abstract][Full Text] [Related]
9. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
[TBL] [Abstract][Full Text] [Related]
10. Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients.
Grzegorzewska AE; Mlot M
Adv Perit Dial; 2005; 21():188-93. PubMed ID: 16686316
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of the intact PTH test with the total PTH test in hemodialyzed patients].
Pecovnik Balon B; Puklavec L; Hojs R
Acta Med Croatica; 2003; 57(1):69-70. PubMed ID: 12876868
[TBL] [Abstract][Full Text] [Related]
12. Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus.
Inaba M; Nagasue K; Okuno S; Ueda M; Kumeda Y; Imanishi Y; Shoji T; Ishimura E; Ohta T; Nakatani T; Kim M; Nishizawa Y
Am J Kidney Dis; 2002 Jun; 39(6):1261-9. PubMed ID: 12046040
[TBL] [Abstract][Full Text] [Related]
13. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.
Kokuho T; Toya Y; Kawaguchi Y; Tamura K; Iwatsubo K; Dobashi Y; Nakazawa A; Takeda H; Iwatsubo M; Hirawa N; Yasuda G; Ohnishi T; Umemura S
Ther Apher Dial; 2007 Dec; 11(6):442-8. PubMed ID: 18028171
[TBL] [Abstract][Full Text] [Related]
14. [CIP and CAP fragments of parathormone and selected parameters of calcium-phosphate balance in patients with chronic kidney disease treated with repeated haemodialysis].
Polak-Jonkisz D; Zwolińska D; Nahaczewska W
Pediatr Endocrinol Diabetes Metab; 2010; 16(1):25-8. PubMed ID: 20529602
[TBL] [Abstract][Full Text] [Related]
15. The role of cyclase activating (CAP) and cyclase inhibiting (CIP) parathormone fractions in the assessment of bone metabolism disturbances in women with hyperprolactinemia of various origin.
Zadrozna-Sliwka B; Bolanowski M; Jawiarczyk A; Kaluzny M; Syrycka J
Neuro Endocrinol Lett; 2008 Feb; 29(1):178-84. PubMed ID: 18283239
[TBL] [Abstract][Full Text] [Related]
16. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
17. OPG, RANK-L, bone metabolism, and BMD in patients on peritoneal dialysis and hemodialysis.
Wittersheim E; Mesquita M; Demulder A; Guns M; Louis O; Melot C; Dratwa M; Bergmann P
Clin Biochem; 2006 Jun; 39(6):617-22. PubMed ID: 16530745
[TBL] [Abstract][Full Text] [Related]
18. Correlation of serum parathormone level with biochemical parameters in chronic renal failure.
Rahman MH; Hossain MM; Sultana S; Jamal CY; Karim MA
Indian Pediatr; 2005 Mar; 42(3):250-4. PubMed ID: 15817973
[TBL] [Abstract][Full Text] [Related]
19. Biochemical markers of bone turnover in the diagnosis of renal osteodystrophy in dialyzed children.
Baskin E; Beşbaş N; Saatçi U; Hasçelik G; Topaloğlu R; Ozen S; Bakkaloğlu A
Turk J Pediatr; 2004; 46(1):28-31. PubMed ID: 15074371
[TBL] [Abstract][Full Text] [Related]
20. Serum osteoprotegerin and renal osteodystrophy.
Coen G; Ballanti P; Balducci A; Calabria S; Fischer MS; Jankovic L; Manni M; Morosetti M; Moscaritolo E; Sardella D; Bonucci E
Nephrol Dial Transplant; 2002 Feb; 17(2):233-8. PubMed ID: 11812872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
